Skip to main content
Download PDF

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

BMC Cancer volume 24, Article number: 487 (2024) Cite this article

The Original Article was published on 08 April 2024

Correction: BMC Cancer 24, 430 (2024)

https://doi.org/10.1186/s12885-024-12155-3


Following publication of the original article [1], the authors noticed that Fig. 4 was a duplicate of Fig. 3.

This correction article consists of the correct Fig. 3 and Fig. 4.

Fig. 3
figure 1

3A, PFS according to PD-L1 CPS classes; 3B, OS according to PD-L1 CPS classes; 3C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3E, PFS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes; 3F, OS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes

Full size image
Fig. 4
figure 2

4A, PFS according to ECOG PS classes; 4B, OS according to ECOG PS classes; 4C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4E, PFS in patients treated with pembrolizumab monotherapy according to ECOG PS classes; 4F, OS in patients treated with pembrolizumab monotherapy according to ECOG PS classes

Full size image

The original article [1] has been corrected.

Reference

  1. Cirillo A, Marinelli D, Romeo U, et al. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis. BMC Cancer. 2024;24:430. https://doi.org/10.1186/s12885-024-12155-3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy

    Alessio Cirillo, Daniela Messineo, Francesca De Felice, Silvia Mezi, Luca Vivona, Antonella Chiavassa & Andrea Botticelli

  2. Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy

    Daniele Marinelli

  3. Department of Oral Sciences and Maxillofacial Surgery, Sapienza University, 00161, Rome, Italy

    Umberto Romeo, Valentino Valentini, Filippo Valentini & Antonella Polimeni

  4. Department of Sense Organs, Sapienza University, 00161, Rome, Italy

    Marco De Vincentiis

  5. Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, 04100, Latina, Italy

    Bruna Cerbelli & Daniele Santini

  6. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121, Brescia, Italy

    Paolo Bossi

  7. Istituto Dermopatico Dell’Immacolata (IDI-IRCCS), 00167, Rome, Italy

    Paolo Marchetti

Authors
  1. Alessio Cirillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Marinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umberto Romeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniela Messineo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesca De Felice
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco De Vincentiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valentino Valentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Silvia Mezi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Filippo Valentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luca Vivona
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Antonella Chiavassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Bruna Cerbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Daniele Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Paolo Bossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Antonella Polimeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Paolo Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Andrea Botticelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Marinelli.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cirillo, A., Marinelli, D., Romeo, U. et al. Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis. BMC Cancer 24, 487 (2024). https://doi.org/10.1186/s12885-024-12249-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12249-y

BMC Cancer

ISSN: 1471-2407

Contact us